Skip to main content

Table 4 Predictors of outcomes or relapses in ANAS patients in multivariate analysis

From: Anti-neuron antibody syndrome: clinical features, cytokines/chemokines and predictors

In 110 ANAS patients

In 51 ANAS patients with CSF

Outcomes

OR(95%CI)

p

Outcomes

OR(95%CI)

p

Tumours

10.156(1.458-70.748)

0.0193

Tumours

13.859 (2.242-85.683)

0.0047

Types of onset

13.921(1.279-151.586)

0.0306

   
   

Relapses

Per-SD increase [OR(95%CI)]

p

   

serum TGFβ1/serum CXCL13

5.809 (1.349-25.002)

0.0182

   

CSF BAFF

0.038(0.001-0.988)

0.0491

  1. ANAS anti-neuron antibody syndrome, OR odds ratio, CI confidence interval, CSF cerebrospinal fluid, SD standard deviation, TGFβ1 transforming growth factor β1, CXCL C-X-C motif chemokine, BAFF B cell activating factor